Phase II Clinical trial of personalized peptide vaccine for cancer patients - Effect of extended dose interval on the immun induction
Phase 2
- Conditions
- malignant tumor
- Registration Number
- JPRN-UMIN000006927
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of use effective contraception during and for at least 70 days after study participation. 4) Patients who are judged inappropriate for the clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of immunological responses (anti-peptide IgG) before and after 3 dose vaccination.
- Secondary Outcome Measures
Name Time Method Adverse effects and safety of peptide vaccination is evaluated based on the CTCAE Version 4.0 .